A Randomized, Double-Blind, Active Placebo-Controlled, Multicenter Efficacy and Safety Pilot Study of OKV-1001 for the Treatment of Primary (Non- Associative) Canine Immune-Mediated Hemolytic Anemia
Principal Investigator: John Loftus
Co-PI: Robert Goggs
Department of Clinical Sciences
Email: jpl249@cornell.edu
Sponsor: Okava Pharmaceuticals Inc
Title: A Randomized, Double-Blind, Active Placebo-Controlled, Multicenter Efficacy and Safety Pilot Study of OKV-1001 for the Treatment of Primary (Non- Associative) Canine Immune-Mediated Hemolytic Anemia
Project Amount: $199,942
Project Period: November 2021 to November 2024